The first domestic 1.1 class anti-ED innovative drug exhibition hard core strength!

Accompanied by the New Year's bell, the first original anti-ED drug in China, Alix® Addenafil Citrate, was approved by the State Food and Drug Administration
.
A few days ago, the reporter learned from the release and sales signing ceremony of AIRIS® Addenafil Citrate Tablets that the product has been fully launched on Alibaba Health Pharmacy and other major e-commerce platforms, chain pharmacies, hospitals and clinics at all levels.
In the red ocean of men's physical health, the strong draws its own blue zone
.
This also means that the competition in the domestic anti-ED drug market will become more and more fierce.
Who will control the ups and downs in the future? Undoubtedly, strong brand power and product power will lead to the restructuring of the market structure
.
It is reported that Alix® Aidinafil Citrate is developed and produced by Yuekang Pharmaceutical, which is a major project of the Ministry of Science and Technology of the National "863" Plan of the "Tenth Five-Year Plan" and a major new drug creation project of the "Twelfth Five-Year Plan".
Academician Guo Yinglu of the National Academy of Engineering He led a team to guide clinical trials, and obtained ten national authoritative institutions such as Peking University People's Hospital and Chinese People's Liberation Army General Hospital to participate in clinical verification
.
As the first 1.
1 class anti-ED original research drug in China, AIRIS has a new chemical structure, unique pharmacokinetics, good safety, high efficacy, and little influence by diet.
It has been approved in China, the United States, the European Union, 22 countries and regions including Russia, Japan, Canada and South Korea have obtained patents
.
Academician Guo Yinglu, academician of the Chinese Academy of Engineering and leader of the Chinese Department of Urology and Andrology, said frankly that the successful listing of AIRIS® Addenafil Citrate represents a qualitative leap in the innovation and scientific research strength of domestic pharmaceutical companies, and contributes to the promotion of Chinese men's health.
It has made positive contributions to the cause and provided new ideas and options for clinical optimization of diagnosis and treatment.
It is a remarkable "Chinese innovation"
.
Fierce competition in the anti-ED market With the advent of the three-child era, how to improve the level of prenatal and postnatal care has become a hot issue of social concern, and men's health has received more attention than ever before
.
The 2022 "White Paper on Chinese Men's Physiological Health" (hereinafter referred to as the "White Paper") shows that men's demands for health are increasing, and more than 80% of men have begun to improve their health and sexual function through physical maintenance
.
The survey found that nearly 20% of adult men over the age of 18 who had sexual experience had a higher degree of erectile dysfunction (ED)
.
After being told they had erectile dysfunction, most men expressed their willingness to seek scientific treatment
.
Currently, the best-selling anti-ED varieties on the market include sildenafil, tadalafil, and vardenafil
.
The data shows that Sildenafil that has been listed in China mainly includes Viagra from Pfizer, Jin Ge from Baiyunshan, Wanfeile from Yabang Epson, Wanyeqiang from Changshan Biochemical, and Ao from Chengdu Diao Pharmaceutical.
Ge, Li Ge of Jilin Jinheng and Qianwei of Qilu Pharmaceutical
.
According to the data of Minet.
com, in the past three years, the total sales volume of sildenafil, tadalafil and vardenafil in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities has increased year by year, and it is expected to hit 4 billion in 2021.
Yuan, the market potential of this category is continuing to explode
.
The total sales of major anti-ED drugs in the past three years (unit: 100 million yuan) From the perspective of the listed brands, the current anti-ED drug market is mainly a battle between domestic brands and original research drugs
.
The data shows that the sales of the original researched sildenafil and tadalafil tablets in Chinese public medical institutions have shown a rapid decline in sales, while in Chinese urban physical pharmacy terminals have risen slowly, while some domestic brands have benefited from the new medical reform policy.
The scale shows a trend of continuous and rapid increase
.
According to public data, the top three domestic sildenafil market share companies in 2019 are Baiyunshan 48.
1%, Pfizer 46.
9%, and Yabang Epson 3.
7%
.
It can be seen that with the improvement of the research and development strength of domestic pharmaceutical companies, consumers' trust in domestic brands is also gradually increasing
.
The data from the white paper also confirms this trend: nearly 60% of men are willing to try newly developed domestic anti-ED drugs, and nearly 50% of men believe that domestic drugs are more suitable for Chinese people's physique
.
It is believed that with the launch of AIRIS® Addenafil Citrate, the anti-ED drug market will make waves again
.
China's innovation shows its hard-core strength For a long time, the production of generic drugs has been plagued by the problem of "only imitating drugs, not imitating processes, processes and crystal forms".
The use of original research drugs has also caused concerns about differences in drug use due to differences in constitutions between China and the West.

.
With the continuous attention and support of the national drug administration on innovative drugs, in order to meet the drug needs of Chinese people, new drug research and development has become a key point of competition among pharmaceutical companies
.
According to statistics, the number of innovative drugs approved in China in 2021 will reach a record high of 68, an increase of 50% over 2020
.
And the local innovation force continues to grow.
From the perspective of the proportion of approvals, domestic innovative drugs will account for 42.
6% of the approval in 2021, and China's innovation has shown its hard core strength
.
As the world's first anti-ED1.
1 innovative drug developed for Chinese men's physiological characteristics in 2021, AIRIS® Eddenafil Citrate has taken Chinese men's physiological characteristics as a reference for drug development from project establishment to research and development.
It has made comprehensive innovations and improvements in the aspects of drug space structure, molecular docking model, target selection specificity, in vivo absorption and metabolism, and drug dosage
.
Professor Xin Zhongcheng of the Second Hospital of Tianjin Medical University introduced that domestic and foreign academic guidelines clearly pointed out that the preferred treatment for ED is oral phosphodiesterase type 5 inhibitor (PDE-5 inhibitor)
.
Prior to this, the PDE-5 inhibitors that have been marketed in China are all foreign research and development products and generic drug products
.
During the exchange, Professor Xin Zhongcheng pointed out that the new drug molecular structure is one of the advantages of idenafil
.
Clinical trial data show that, compared with sildenafil, tadalafil, etc.
, although aldenafil tablets belong to the same family of PDE5 inhibitors, they have made overall progress in erection hardness, penetration rate, and safety
.
In addition, AIRIS® Eddenafil Citrate also has obvious characteristics in chemical structure
.
The interaction with PDE-5 is strong and specific, and its target inhibitory activity for the treatment of erectile dysfunction is superior to similar products
.
At the same time, the drug-related adverse events of idenafil citrate tablets are less, and the incidence rate is lower than that of similar products reported in the literature
.
Undoubtedly, the essence of innovative drugs is to solve unmet clinical needs
.
With the promotion of policies, the continuous acceleration of review and approval, and the development of technology, the research and development of innovative drugs is undoubtedly one of the most determined directions for the future medical market, and the era of innovative drugs in China is coming
.
Facing the tide of the times, Yu Weishi, chairman of Yuekang Pharmaceutical Group Co.
, Ltd.
, has a clear plan: "Continue to increase the research and innovation of innovative drugs and high-end drugs, focus on unmet medical needs, through research and development innovation and The transformation of scientific research will bring more high-quality innovative drugs to patients
.
"